Table 1.
Observed crude point prevalence and iSPR of prespecified comorbidities among patients in the PBC population or the PBC-pruritus subpopulation relative to the respective non-case population
| Comorbidity | PBC population (N=1963) |
PBC-pruritus subpopulation (N=139) |
Non-case population (N=10 245 592)* | ||
| % | iSPR (95% CI)† | % | iSPR (95% CI)† | % | |
| PBC symptoms of interest | |||||
| Diarrhoea | 9.3 | 2.38 (2.05 to 2.75) | 13.7 | 3.73 (2.25 to 5.83) | 3.1 |
| Pruritus | 6.8 | 3.24 (2.71 to 3.84) | N/A | N/A | 1.5 |
| UTI | 13.8 | 1.37 (1.21 to 1.54) | 13.0 | 1.36 (0.81 to 2.15) | 6.6 |
| Prevalent psychiatric and other conditions affecting QoL | |||||
| Cognitive impairment | 3.1 | 1.00 (0.77 to 1.29) | 4.3 | 1.77 (0.65 to 3.85) | 1.7 |
| Depression or anxiety | 21.3 | 1.09 (0.99 to 1.20) | 28.1 | 1.46 (1.04 to 2.00) | 15.9 |
| Fatigue | 19.9 | 1.51 (1.36 to 1.66) | 26.6 | 2.10 (1.48 to 2.90) | 10.4 |
| Sleep-related issues | 6.9 | 1.18 (0.99 to 1.40) | 14.4 | 2.58 (1.58 to 3.99) | 4.4 |
| Liver and autoimmune conditions | |||||
| Autoimmune hepatitis | 9.5 | 151.31 (130.40 to 174.62) | 12.2 | 218.07 (127.03 to 349.15) | 0.03 |
| Autoimmune thyroid disease | 3.0 | 2.09 (1.59 to 2.70) | 4.3 | 2.92 (1.07 to 6.36) | 1.0 |
| Raynaud’s syndrome | 2.9 | 7.75 (5.87 to 10.04) | 2.9 | 7.72 (2.10 to 19.75) | 0.2 |
| Rheumatoid arthritis | 6.3 | 2.89 (2.40 to 3.45) | 5.0 | 2.58 (1.04 to 5.31) | 1.2 |
| Sjögren’s syndrome | 5.8 | 11.64 (9.60 to 13.98) | 11.5 | 25.20 (14.40 to 40.93) | 0.2 |
| SLE | 2.4 | 4.91 (3.60 to 6.52) | 1.4 | 2.95 (0.36 to 10.67) | 0.3 |
*N for the non-case population (N=10 245 592), relates to the comparison versus the PBC population not vs the PBC-pruritus population (N=9 984 009).
†Compared with non-case population.
CI, confidence interval; iSPRs, indirect age-sex standardised prevalence ratios; N/A, not applicable; PBC, primary biliary cholangitis; QoL, quality of life; SLE, systemic lupus erythematosus; UTI, urinary tract infection.